Home » Newsletters » BioWorld Science

BioWorld Science

March 23, 2005

View Archived Issues

European Society of Cardiology guidelines recommend bivalirudin

Insmed and UCSF sign option agreement for IGF-1 receptor antagonists

Enzon terminates Marqibo agreement

Boehringer Ingelheim and MorphoSys expand cooperative efforts

Viragen anti-CD55 antibody enhances effect of Rituxan

sanofi pasteur seeks to broaden age group for Menactra vaccine

Cytogen updates Quadramet development efforts

Innovive licenses opioid growth factor from Penn State

Progression-free survival findings from ongoing CONFIRM 1 study

Combunox launched

ISTA submits IND for phase IIb study of ecabet sodium for dry eye syndrome

Dynavax Technologies and UCB end seasonal allergies collaboration

PhotoMedex and ProCyte shareholders approve merger

Teva issues reassurance on safety of Copaxone

Enrollment complete in pivotal study of panitumumab for colorectal cancer

Eupatilin reduces histamine release and leukotriene synthesis in OVA-sensitized mast cells

Therapeutic potential of CRIC-3 confirmed in murine models of allergic asthma

PD-0305970 displays excellent in vivo activity against Gram-positive bacterial infections

Tarceva approved in Switzerland for NSCLC

BMS discovers IGF-1R inhibitor with broad-spectrum in vivo antitumor activity

Treatment with CCR5 antagonist spares monkeys from collagen-induced arthritis

R-112 significantly improves symptoms of seasonal allergic rhinitis

New data on small and ultrasmall particles of iron oxide as contrast agents for MRI

Anti-TNF agent SD-06 in phase I trials

Potent and highly selective p38alpha MAPK inhibitor selected as a clinical candidate

Ixabepilone demonstrates activity in castrate metastatic prostate cancer

Experiments reveal activity of D-4F in asthma model

New treatments for psychotic disorders described in patent literature

AstraZeneca discloses JNK3 inhibitors

Antibacterial oxazolidinones described in a patent